Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2025 16:01 ET | Source: Boundless Bio, Inc.

Boundless Bio Announces Portfolio Prioritization and Runway Extension

Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first...
May 09, 2025 07:00 ET | Source: Boundless Bio, Inc.

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for...
April 03, 2025 07:00 ET | Source: Boundless Bio, Inc.

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...
March 27, 2025 07:00 ET | Source: Boundless Bio, Inc.

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward...
February 26, 2025 07:00 ET | Source: Boundless Bio, Inc.

Boundless Bio to Participate in the Leerink Global Healthcare Conference

SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...
February 03, 2025 10:00 ET | Source: Boundless Bio, Inc.

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...
December 12, 2024 16:01 ET | Source: Boundless Bio, Inc.

Boundless Bio Announces Pipeline and Leadership Updates

Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway...
November 25, 2024 07:00 ET | Source: Boundless Bio, Inc.

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...
November 07, 2024 16:01 ET | Source: Boundless Bio, Inc.

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating...
November 05, 2024 07:00 ET | Source: Boundless Bio, Inc.

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...